全文获取类型
收费全文 | 975篇 |
免费 | 93篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 38篇 |
妇产科学 | 16篇 |
基础医学 | 182篇 |
口腔科学 | 12篇 |
临床医学 | 57篇 |
内科学 | 228篇 |
皮肤病学 | 11篇 |
神经病学 | 40篇 |
特种医学 | 98篇 |
外科学 | 135篇 |
综合类 | 4篇 |
预防医学 | 39篇 |
眼科学 | 7篇 |
药学 | 21篇 |
中国医学 | 2篇 |
肿瘤学 | 194篇 |
出版年
2023年 | 9篇 |
2022年 | 11篇 |
2021年 | 18篇 |
2020年 | 15篇 |
2019年 | 17篇 |
2018年 | 37篇 |
2017年 | 23篇 |
2016年 | 14篇 |
2015年 | 27篇 |
2014年 | 26篇 |
2013年 | 40篇 |
2012年 | 51篇 |
2011年 | 48篇 |
2010年 | 48篇 |
2009年 | 43篇 |
2008年 | 39篇 |
2007年 | 48篇 |
2006年 | 33篇 |
2005年 | 30篇 |
2004年 | 26篇 |
2003年 | 29篇 |
2002年 | 23篇 |
2001年 | 22篇 |
2000年 | 22篇 |
1999年 | 12篇 |
1998年 | 22篇 |
1997年 | 16篇 |
1996年 | 17篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 20篇 |
1992年 | 13篇 |
1991年 | 10篇 |
1990年 | 18篇 |
1989年 | 25篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 24篇 |
1985年 | 17篇 |
1984年 | 9篇 |
1983年 | 14篇 |
1982年 | 10篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1979年 | 4篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1973年 | 4篇 |
排序方式: 共有1089条查询结果,搜索用时 15 毫秒
91.
Maggie KM Ma Helen KW Law Kin Sun Tse Kwok Wah Chan Gary CW Chan Desmond YH Yap Maggie MY Mok Lorraine PY Kwan Sydney CW Tang Bo Ying Choy Tak Mao Chan 《International journal of urology》2018,25(5):450-455
Objectives
To evaluate the use of shear wave elastography in assessment of kidney allograft tubulointerstitial fibrosis.Methods
Shear wave elastography assessment was carried out by two independent operators in kidney transplant recipients who underwent allograft biopsy for clinical indications (i.e. rising creatinine >15% or proteinuria >1 g/day). Allograft biopsies were interpreted by the same pathologist according to the 2013 Banff Classification.Results
A total of 40 elastography scans were carried out (median creatinine 172.5 μmol/L [interquartile range 133.8–281.8 μmol/L]). Median tissue stiffness at the cortex (22.6 kPa [interquartile range 18.8–25.7 kPa] vs 22.3 kPa [interquartile range 19.0–26.5 kPa], P = 0.70) and medulla (15.0 kPa [interquartile range 13.7–18.0 kPa] vs 15.6 kPa [interquartile range 14.4–18.2 kPa]) showed no significant differences between the two observers. Interobserver agreement was satisfactory (intraclass correlation coefficient of the cortex 0.84, 95% CI 0.70–0.92 and intraclass correlation coefficient of the medulla 0.88, 95% CI 0.78–0.94). The areas under the receiver operating characteristic curves for detection of tubulointerstitial fibrosis were estimated to be 0.75 (95% CI 0.61–0.89), 0.85 (95% CI 0.75–0.95) and 0.65 (95% CI 0.53–0.78) for cortical, medullary tissue stiffness and serum creatinine, respectively.Conclusions
Shear wave elastography can be used as a non‐invasive tool to evaluate kidney allograft fibrosis with reasonable interobserver agreement and superior test performance to serum creatinine in detecting early tubulointerstitial fibrosis. 相似文献92.
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida 总被引:4,自引:0,他引:4 下载免费PDF全文
Cacciapuoti A Loebenberg D Corcoran E Menzel F Moss EL Norris C Michalski M Raynor K Halpern J Mendrick C Arnold B Antonacci B Parmegiani R Yarosh-Tomaine T Miller GH Hare RS 《Antimicrobial agents and chemotherapy》2000,44(8):2017-2022
SCH 56592 (posaconazole), a new triazole antifungal agent, was tested in vitro, and its activity was compared to that of itraconazole against 39 Aspergillus strains and to that of fluconazole against 275 Candida and 9 Cryptococcus strains. The SCH 56592 MICs for Aspergillus ranged from =0.002 to 0.5 microg/ml, and those of itraconazole ranged from =0.008 to 1 microg/ml. The SCH 56592 MICs for Candida and Cryptococcus strains ranged from =0. 004 to 16 microg/ml, and those of fluconazole ranged from =0.062 to >64 microg/ml. SCH 56592 showed excellent activity against Aspergillus fumigatus and Aspergillus flavus in a pulmonary mouse infection model. When administered therapeutically, the 50% protective doses (PD(50)s) of SCH 56592 ranged from 3.6 to 29.9 mg/kg of body weight, while the PD(50)s of SCH 56592 administered prophylactically ranged from 0.9 to 9.0 mg/kg; itraconazole administered prophylactically was ineffective (PD(50)s, >75 mg/kg). SCH 56592 was also very efficacious against fluconazole-susceptible, -susceptible dose-dependent, or -resistant Candida albicans strains in immunocompetent or immunocompromised mouse models of systemic infection. The PD(50)s of SCH 56592 administered therapeutically ranged from 0.04 to 15.6 mg/kg, while the PD(50)s of SCH 56592 administered prophylactically ranged from 1.5 to 19.4 mg/kg. SCH 56592 has excellent potential for therapy against serious Aspergillus or Candida infections. 相似文献
93.
H McGrath E Bak M L Zimny J P Michalski 《Journal of clinical & laboratory immunology》1990,32(3):113-116
Fluorescent light emitted from cool white tubular fluorescent lamps covered with standard acrylic lids decreased autoimmunity and enhanced immunity in the New Zealand Black/New Zealand White F1 hybrid female (B/W) mouse model of systemic lupus erythematosus (SLE). Thirty-three weeks of daily cool white fluorescent light exposure significantly decreased anti-ds DNA antibody levels and spleen size, and increased lymphocyte responsiveness to lipopolysaccharide (LPS) in B/W mice depilated to enhance light penetration. Depilation alone had no significant effect. The immunomodulatory potential of fluorescent light in B/W mice has not been previously appreciated, and may have important implications in SLE. 相似文献
94.
Kate Vandyke Andrea L Dewar Peter Diamond Stephen Fitter Christopher G Schultz Natalie A Sims Andrew CW Zannettino 《Journal of bone and mineral research》2010,25(8):1759-1770
Dasatinib is a potent tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients resistant or intolerant to imatinib mesylate. While designed to inhibit Abl and Src kinases, dasatinib shows multitarget effects, including inhibition of the macrophage colony‐stimulating factor (M‐CSF) receptor c‐fms. We have shown previously that dasatinib abrogates osteoclast formation and activity in vitro owing, in part, to its specificity for c‐fms. In this study we examined whether dasatinib could significantly alter bone volume in a model of physiologic bone turnover. Sprague‐Dawley rats were administered dasatinib (5 mg/kg/day) or vehicle by gavage or zoledronic acid (ZOL; 100 µg/kg/6 weeks) subcutaneously. Following 4, 8, and 12 weeks of treatment, serum biochemical, bone morphometric, and histologic analyses were performed. Whole‐body bone mineral density and tibial cortical thickness where unchanged in the dasatinib‐ or ZOL‐treated animals relative to controls. However, micro–computed tomographic (µCT) analysis of cancellous bone at the proximal tibias showed that trabecular volume (BV/TV) and thickness (Tb.Th) were increased in dasatinib‐treated animals at levels comparable with those of the ZOL‐treated group. These changes were associated with a decrease in osteoclast numbers (N.Oc/B.Pm) and surface (Oc.S/BS) and decreased serum levels of the osteoclast marker c‐terminal collagen crosslinks (CTX‐1). Mineral apposition rate (MAR), bone‐formation rate (BFR), and levels of the serum osteoblast markers osteocalcin and N‐terminal propeptide of type I procollagen (P1NP) were not altered significantly in the dasatinib‐treated animals relative to controls. These studies show that dasatinib increases trabecular bone volume at least in part by inhibiting osteoclast activity, suggesting that dasatinib therapy may result in dysregulated bone remodeling. © 2010 American Society for Bone and Mineral Research 相似文献
95.
Hüser N Assfalg V Michalski CW Gillen S Kleeff J Friess H 《Zentralblatt für Chirurgie》2010,135(6):502-507
In most cases pancreatic cancer appears in a non-curatively resectable stage at time the diagnosis is made. Thus, palliative treatment concepts come to the fore in these patients. Patients without metastases, but presenting with marginally resectable or locally non-resectable tumours should not be treated in a palliative therapeutic scheme. These patients should be enrolled in neoadjuvant radiochemotherapy trials. After finishing treatment and restaging, a potentially curative resection can be achieved in approximately one-third of these patients. Within the scope of the best possible palliative care, excision of metastases together with resection of the primary cancer represents a therapeutic option to be contemplated in selected cases. For distinct locally unresectable or metastasised advanced pancreatic cancer, treatment of bile duct or duodenal obstruction is an essential part of the comprehensive palliative therapy. However, both endoscopic?/?percutaneous stenting procedures and surgical bypass makeshifts constitute safe and highly effective therapeutic alternatives in this context. In the case of operative drainage of the biliary tract the prophylactic creation of a gastro-intestinal bypass (double bypass) is recommended. The decision on a surgical versus an endoscopic procedure for palliation depends considerably on the tumour stage and the estimated prognosis and has to be determined interdisciplinary and individually in each case. 相似文献
96.
Peter Diamond Agatha Labrinidis Sally K Martin Amanda N Farrugia Stan Gronthos L Bik To Nobutaka Fujii Peter D O'Loughlin Andreas Evdokiou Andrew CW Zannettino 《Journal of bone and mineral research》2009,24(7):1150-1161
The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)‐mediated skeletal destruction. We have previously shown that elevated plasma levels of PC‐derived CXCL12 are associated with presence of X‐ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC‐mediated bone resorption was identified. To confirm the OC‐activating potential of MM PC‐derived CXCL12 in vivo, we established a model of MM‐mediated focal osteolysis, wherein MM PC lines, such as RPMI‐8226, were injected into the tibias of nude mice. Implanting RPMI‐8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist T140. Furthermore, implanting CXCL12‐overexpressing RPMI‐8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC‐derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions. 相似文献
97.
Ramses G Forsyth Gitte De Boeck Johannes J Baelde Anthonie HM Taminiau Dirk Uyttendaele Hendrik Roels Marleen M Praet Pancras CW Hogendoorn 《Journal of bone and mineral research》2009,24(1):70-77
Giant cell tumor of bone (GCTB) is a benign bone tumor with a shown clinical behavior of local recurrences and rare distant metastases. GCTB is composed of uniformly distributed osteoclastic giant cells, thought to originate from the fusion of monocyte–macrophage lineage cells, in a background consisting of mononuclear rounded cells and spindle‐shaped cells. Several reports showed the specific expression of markers, such as CD14 on the mononuclear rounded cell population, however, lacking osteoclastic giant cells. Blood monocytes that were CD14+, CD33+, or CD14+/CD33+ have also been shown to be programmed as pre‐osteoclasts. The macrophage marker CD33 is expressed earlier than CD14 in macrophage maturation, whereas CD14 is expressed longer than CD33. The aim of this study was to investigate CD14/CD33 expression profiles in GCTB. Nineteen GCTB tumor samples of 19 patients were studied. Immunofluorescent analyses were performed with monoclonal antibodies against CD14, CD33, RANK, and CD51. To unambiguously further prove the expression of these molecules, quantitative RT‐PCR was used with subsequent sequencing of its products. All samples showed similar immunoreactivity profiles. The mononuclear rounded cell population was positive for RANK, CD51, CD14, and CD33. The osteoclastic giant cell population expressed RANK and CD51, as well as CD33, but was consistently negative for CD14 expression. The CD14 and CD33 profiles were confirmed by quantitative RT‐PCR. These RT‐PCR products were sequence verified. Osteoclasts in GCTB are the result of fusion of CD33‐expressing pre‐osteoclasts that further fuse with CD14+ mononuclear cells. Although these results reflect a static rather than a dynamic spectrum, we strongly believe that osteoclastogenesis seems not to be the exclusive result of fusion of intratumoral CD14+ mononuclear cells. Moreover, CD33‐modulated osteoclastogenesis opens up the possibility for novel therapeutic directions. 相似文献
98.
Ba O Almeida F Fondronnier C Michalski M Gossot D Savinelli F Le Maignan C Misset JL Trédaniel J 《Revue de pneumologie clinique》2007,63(2):100-103
INTRODUCTION: Metastatic involvement of the peritoneum from a lung cancer is infrequently encountered. METHODS: We present the case report of a patient with bronchial adenocarcinoma whose course is complicated by the occurrence of a peritoneal carcinomatosis, as documented by FDG-PET. CONCLUSION: Unexplained abdominal pain in a lung cancer patient may be a peritoneal carcinomatosis. The diagnosis can be helped by PET-scan. However, the therapeutic opportunities are very limited. 相似文献
99.
Frank SJ Grimm PD Sylvester JE Merrick GS Davis BJ Zietman A Moran BJ Beyer DC Roach M Clarke DH Stock RG Robert Lee W Michalski JM Wallner KE Hurwitz M Potters L Kuban DA Prestidge BR Vera R Hathaway S Blasko JC 《Brachytherapy》2007,6(1):2-8
PURPOSE: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. METHODS AND MATERIALS: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) > or = 7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3+4 vs. 4+3, and high-volume disease were included. RESULTS: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3+4) or PSA 10-20, with cT1c and <30% cores +. Up to 80% would perform monotherapy for patients with cT1c, GS 7 (4+3), and <30% cores +. Eighty to 90% of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3+4) and <30% cores +. Fifty to 60% of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3+4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. CONCLUSIONS: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone. 相似文献
100.